Guggenheim Maintains Buy on Biogen, Raises Price Target to $280

Benzinga Newsdesk www.benzinga.com Positive 71.3%

Neg 0% Neu 0% Pos 71.3%

Guggenheim analyst Brad Canino maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.

Comments

No comments yet. Be the first!